Insight Molecular Diagnostics Inc.
IMDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001642380
No open-market purchases or sales by Insight Molecular Diagnostics Inc. insiders were filed in the last 90 days; 40 institutions reported holding it in 13F filings for Q2 2026, worth $108.9M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Insight Molecular Diagnostics Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 52 | 47 | −5 |
| Shares | 55.7M | 91.8M | +36.2M (+65.0%) |
| Value | $19.7M | $21.1M | +$1.40M (+7.1%) |
New holders (6)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 251,952 | $57.9K | 0.00% |
| Virtu Financial LLC | 65,123 | $15.0K | 0.00% |
| HRT Financial LP | 27,321 | $6.00K | 0.00% |
| Creative Planning | 12,136 | $2.79K | 0.00% |
| Rhumbline Advisers | 1,323 | $304 | 0.00% |
| Coppell Advisory Solutions LLC | 205 | $44 | 0.00% |
Sold out (11)
Institutions that held Insight Molecular Diagnostics Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Penbrook Management LLC | 207,675 | $73.6K |
| Bridgeway Capital Management, LLC | 205,300 | $72.8K |
| Charles Schwab Investment Management Inc | 62,284 | $22.1K |
| Susquehanna International Group, LLP | 34,776 | $12.3K |
| Deutsche Bank AG | 33,890 | $12.0K |
| Jane Street Group, LLC | 24,806 | $8.79K |
| Westshore Wealth, LLC | 20,000 | $7.09K |
| Freestone Capital Holdings, LLC | 10,000 | $3.54K |
| LMR Partners LLP | 10,000 | $3.54K |
| Citigroup Inc | 137 | $49 |
| Group One Trading, L.P. | 24 | $9 |